Physician profile
Eleazar Vera
NPI 1407822299
$1,763.82
in general payments reported to CMS, 2019-2025
15 companies · $74.71 in 2025
The $74.71 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457 · 2020: $262 · 2021: $232 · 2022: $207 · 2023: $356 · 2024: $175 · 2025: $74.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $605.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $448.88 | 2019-2024 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $325.07 | 2019-2024 | Repatha |
| Novo Nordisk INC | $191.48 | 2019-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $178.44 | 2021-2025 | Farxiga |
| Amarin Pharma, INC. | $149.87 | 2020 | |
| Merck Sharp & Dohme LLC | $83.90 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.77 | 2021-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $76.42 | 2023 | |
| Abbott Laboratories | $66.55 | 2023 | Jeti |
| Pfizer INC. | $45.45 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.16 | 2022 | |
| Sumitomo Pharma America, INC. | $25.93 | 2025 | Gemtesa |
| Abbvie INC. | $18.40 | 2023 | Qulipta |
| Exact Sciences Corporation | $16.44 | 2025 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $13.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eleazar Vera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.